Elucidation of risk factors and health determinations associated with progression of Monoclonal Gammopathies to Multiple Myeloma

The project aims to investigate the molecular mechanisms and construct a molecular model of cellular processes characterising the pathogenesis and progression of Multiple Myeloma (MM) and response to therapy. The clinical ambition is to find innovative treatment regimens tailored to the specific characteristics of each patient. This aim is to be achieved by a systems medicine approach and interdisciplinary communication bringing together clinical and research partners with expertise in MM, epidemiology, mouse models, omics, bioinformatics, and artificial intelligence (AI).

The consortium is formed by 13 partners including European reference centres, research and academic institutions, SME and innovative biotechnology companies. The territorial scope of the project covers several European countries, such as the National Hellenic Research Foundation, Biomedical Research Foundation of the Academy of Athens, Exelixis Research Management & Communication (Greece), Universita Degli Studi Di Torino (Italy), Universidad de Navarra, ATOS IT Solutions and Services Iberia SL (Spain), Centre National de la Recherche Scientifique CNRS (France), Universitätsklinikum Würzburg, Bayerische Julius-Maximilians-Universität, Gottfried Wilhelm Leibniz Universtität Hannover, Mosaiques Diagnostics GmbH (Germany), The Cyprus Institute of Neurology and Genetics (Cyprus). The LUH, active by the Institut für Rechtsinformatik (IRI), is a legal partner to the project in charge of setting up legal, privacy and ethical framework.